Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

Brings 30+ years of economic expertise within the orthopedic and spine business

BURLINGTON, Mass., October 21, 2024 –(BUSINESS WIRE)– Bone Biologics Company (“Bone Biologics” or the “Firm”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic merchandise for spine fusion markets, proclaims the appointment of Phillip T. Meikle to the Firm’s board of administrators, efficient instantly. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The variety of administrators of Bone Biologics stays at 4.

Mr. Meikle most just lately was president and chief government officer of Biosystems of New England, Inc., an orthopedic distribution firm that he based in 1992 and bought to Stryker Company in 2019. He has broad expertise representing numerous and revolutionary orthopedic and spine business firms in growing and distributing revolutionary merchandise. Mr. Meikle has been a marketing consultant to Stryker Backbone for the previous 5 years.

Biosystems of New England served as a distributor for Stryker Backbone from 2002 to 2019, and for Medtronic Backbone from 1992 to 2002.

“The appointment of Phillip Meikle to our board of administrators is especially well timed as we work to develop NB1 for spinal fusion sufferers. He brings a wealth of expertise with orthopedic and spine merchandise, and we sit up for benefitting from his data, expertise and business relationships. We’re delighted {that a} skilled of Phil’s stature has agreed to affix our board,” mentioned Jeffrey Frelick, president and chief government officer of Bone Biologics. “On behalf of Bone Biologics and our board of administrators, I lengthen heartfelt due to Don Hankey for his service as Chairman and his long-standing assist of our firm, with out which we might not be the place we’re in the present day.”

Mr. Meikle holds a B.S. from West Virginia College School of Engineering. He has acquired quite a few skilled awards together with Inaugural Inductee within the Stryker Backbone Corridor of Fame and Distributor of the 12 months at each Stryker and Medtronic Danek Backbone.

About Bone Biologics

Bone Biologics was based to pursue regenerative medication for bone. The Firm is endeavor work with choose strategic companions that builds on the preclinical analysis of the NELL-1 protein. Bone Biologics is focusing growth efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, whereas moreover having rights to trauma and osteoporosis purposes. For extra data, please go to www.bonebiologics.com.

Ahead-Trying Statements

Sure statements contained on this press launch, together with, with out limitation, statements concerning the anticipated outcomes and efficiency of Mr. Meikle and the flexibility of the corporate to develop the Firm’s lead product candidate NB1 for spinal fusion sufferers, in addition to statements containing the phrases “look ahead” and phrases of comparable import, represent “forward-looking statements” throughout the that means of the Personal Securities Litigation Reform Act of 1995. Such forward-looking statements contain each identified and unknown dangers and uncertainties. The Firm’s precise outcomes might differ materially from these contained in its forward-looking statements because of a variety of elements, together with, however not restricted to, market and different situations and dangers usually related to an undercapitalized growing firm, in addition to the dangers contained underneath “Danger Components” and “Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations” within the Firm’s Annual Report on Type 10-Ok for the 12 months ended December 31, 2023 and the Firm’s different filings with the Securities and Trade Fee. Besides as required by relevant legislation, the Firm undertakes no obligation to revise or replace any forward-looking statements to mirror any occasion or circumstance which will come up after the date hereof.